JP2018519818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519818A5 JP2018519818A5 JP2017566354A JP2017566354A JP2018519818A5 JP 2018519818 A5 JP2018519818 A5 JP 2018519818A5 JP 2017566354 A JP2017566354 A JP 2017566354A JP 2017566354 A JP2017566354 A JP 2017566354A JP 2018519818 A5 JP2018519818 A5 JP 2018519818A5
- Authority
- JP
- Japan
- Prior art keywords
- mol
- composition
- lipid
- mixture
- dodap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 150000002632 lipids Chemical class 0.000 claims 16
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 7
- 230000009368 gene silencing by RNA Effects 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- -1 nucleic acid compound Chemical class 0.000 claims 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 5
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims 5
- 102000000412 Annexin Human genes 0.000 claims 4
- 108050008874 Annexin Proteins 0.000 claims 4
- 108050005845 Annexin A11 Proteins 0.000 claims 4
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims 4
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims 4
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical group C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 3
- 101000614345 Homo sapiens Prolyl 4-hydroxylase subunit alpha-1 Proteins 0.000 claims 2
- 102100040477 Prolyl 4-hydroxylase subunit alpha-1 Human genes 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 229960001295 tocopherol Drugs 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 235000010384 tocopherol Nutrition 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001841 cholesterols Chemical class 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 150000003611 tocopherol derivatives Chemical class 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562190583P | 2015-07-09 | 2015-07-09 | |
| US62/190,583 | 2015-07-09 | ||
| PCT/US2016/041776 WO2017008076A1 (en) | 2015-07-09 | 2016-07-11 | Compositions and methods for treating lung diseases and lung injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519818A JP2018519818A (ja) | 2018-07-26 |
| JP2018519818A5 true JP2018519818A5 (https=) | 2019-09-12 |
| JP6884714B2 JP6884714B2 (ja) | 2021-06-09 |
Family
ID=57686097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566354A Active JP6884714B2 (ja) | 2015-07-09 | 2016-07-11 | 肺疾患及び肺損傷を治療するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180200186A1 (https=) |
| EP (1) | EP3319976B1 (https=) |
| JP (1) | JP6884714B2 (https=) |
| AU (2) | AU2016291228B2 (https=) |
| CA (1) | CA2989884A1 (https=) |
| ES (1) | ES2898340T3 (https=) |
| WO (1) | WO2017008076A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029994T2 (en) | 2005-12-08 | 2017-04-28 | Insmed Inc | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| RU2018135921A (ru) | 2012-11-29 | 2019-02-05 | Инсмед Инкорпорейтед | Стабилизированные составы ванкомицина |
| LT3060041T (lt) | 2013-10-25 | 2021-03-25 | Insmed Incorporated | Prostaciklino junginiai |
| SMT202000516T1 (it) | 2014-05-15 | 2020-11-10 | Insmed Inc | Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| WO2019213398A1 (en) | 2018-05-02 | 2019-11-07 | Insmed Incorporated | Methods for the manufacture of liposomal drug formulations |
| US11517548B2 (en) * | 2018-07-19 | 2022-12-06 | Impel Pharmaceuticals Inc. | Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease |
| CN112996519B (zh) * | 2018-09-04 | 2025-02-28 | 德克萨斯大学系统董事会 | 用于核酸的器官特异性递送的组合物和方法 |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| CN109432047B (zh) * | 2018-10-29 | 2021-07-20 | 中国药科大学 | 一种逆转肺纤维化纳米制剂及其制备方法 |
| JP7455144B2 (ja) | 2019-04-29 | 2024-03-25 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 |
| JP7674354B2 (ja) * | 2019-12-05 | 2025-05-09 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法 |
| GB2632565B (en) | 2020-04-09 | 2025-06-04 | Verve Therapeutics Inc | Base editing of PCSK9 and methods of using same for treatment of disease |
| AU2021305214A1 (en) * | 2020-07-10 | 2023-02-23 | Genevant Sciences Gmbh | Lipid nanoparticles for delivering therapeutics to lungs |
| JP2023549011A (ja) | 2020-09-15 | 2023-11-22 | ヴァーヴ・セラピューティクス，インコーポレーテッド | 遺伝子編集のための脂質製剤 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| JP2024511463A (ja) | 2021-03-22 | 2024-03-13 | リコード セラピューティクス，インク． | 細胞への標的送達のための組成物および方法 |
| CN113058042B (zh) * | 2021-04-01 | 2023-06-30 | 易慧生物技术(上海)有限公司 | 一种可鼻喷的稳定递载rna分子的脂质纳米颗粒制备方法 |
| JP2024520834A (ja) * | 2021-06-09 | 2024-05-24 | レコード・セラピューティクス・インコーポレイテッド | ポリヌクレオチド組成物、関連する製剤及びその使用方法 |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2023019192A1 (en) * | 2021-08-11 | 2023-02-16 | Board Of Regents, The University Of Texas System | Dry liposome formulations and related methods thereof |
| US20240382425A1 (en) * | 2021-08-14 | 2024-11-21 | Bs Biotechna Spolka Z Ograniczona Odpowiedzialnoscia | RNA binding and stabilising cationic liposome, its application and method of loading the liposome with emetine |
| EP4226949A1 (en) * | 2022-02-14 | 2023-08-16 | Pantherna Therapeutics GmbH | Preparation for use in a method for the treatment and/or prevention of a disease |
| WO2024242216A1 (ko) * | 2023-05-23 | 2024-11-28 | 주식회사 케이더블유바이오 | 대식세포 표적화 리포좀 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4721612A (en) * | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
| US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP1666606A4 (en) * | 2003-08-20 | 2006-11-29 | Locomogene Inc | METHODS FOR IDENTIFYING REGULATORY EFFECTS ON THE ACTIVITY OF SYNOVIOLIN |
| CA2587411A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
| CN104119242B (zh) * | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| WO2011108955A1 (en) * | 2010-03-03 | 2011-09-09 | Universidade De Coimbra | Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s) |
| CA2801066C (en) * | 2010-06-02 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| US20140308304A1 (en) * | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| CA2925687A1 (en) * | 2012-09-27 | 2014-04-03 | The University Of North Carolina At Chapel Hill | Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof |
-
2016
- 2016-07-11 EP EP16822088.7A patent/EP3319976B1/en active Active
- 2016-07-11 CA CA2989884A patent/CA2989884A1/en not_active Abandoned
- 2016-07-11 AU AU2016291228A patent/AU2016291228B2/en active Active
- 2016-07-11 WO PCT/US2016/041776 patent/WO2017008076A1/en not_active Ceased
- 2016-07-11 ES ES16822088T patent/ES2898340T3/es active Active
- 2016-07-11 US US15/742,812 patent/US20180200186A1/en not_active Abandoned
- 2016-07-11 JP JP2017566354A patent/JP6884714B2/ja active Active
-
2020
- 2020-05-22 AU AU2020203367A patent/AU2020203367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519818A5 (https=) | ||
| Pramanik et al. | Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases | |
| Wang et al. | Lipid-based antimicrobial delivery-systems for the treatment of bacterial infections | |
| Hernandez et al. | Liposome based drug delivery as a potential treatment option for Alzheimer's disease | |
| JP2025512806A (ja) | ｍＲＮＡ送達方法およびその組成物 | |
| JP2007508353A5 (https=) | ||
| JP2018528184A5 (https=) | ||
| Jain et al. | Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer | |
| JP2018516545A5 (https=) | ||
| JP2015515992A5 (https=) | ||
| JP2014077003A5 (https=) | ||
| Homayoonfal et al. | Application of nanoparticles for efficient delivery of quercetin in cancer cells | |
| Yong et al. | Natural products-based inhaled formulations for treating pulmonary diseases | |
| JP2010508365A5 (https=) | ||
| Abdelaziz et al. | Solid lipid nanoparticle-based drug delivery for lung cancer | |
| Sadhu et al. | In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine | |
| JPWO2022066916A5 (https=) | ||
| Jani et al. | Focused insights into liposomal nanotherapeutics for antimicrobial treatment | |
| JP2008540364A5 (https=) | ||
| Yildiz et al. | Nanoliposomes as nonviral vectors in cancer gene therapy | |
| Ji et al. | Synaptic vesicle-inspired nanoparticles with spatiotemporally controlled release ability as a “nanoguard” for synergistic treatment of synucleinopathies | |
| Song et al. | Microenvironments‐targeted nanomaterials for atherosclerosis therapy | |
| TWI760319B (zh) | 乳癌治療 | |
| Zhang et al. | Liposome-mediated macrophage reprogramming: emerging strategies for chronic disease therapy | |
| US20170050945A1 (en) | Compositions and methods for the treatment of sarcoidosis |